Stage IV/Recurrent Malignant Pleural Mesothelioma
Alimta® and Platinol® (pemetrexed and cisplatin) is the only drug specifically approved by the U.S. Food and Drug Administration for the treatment of inoperable mesothelioma.
The drug combination Alimta®/Platinol® provides the most effective and currently FDA‑approved systemic therapy for patients with stage IV or recurrent malignant pleural mesothelioma, offering increased overall survival and improved quality of life compared to single‑agent therapy.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Moving Beyond Morphology: Toward a Morpho‑Molecular Classification of Pleural Mesothelioma
- Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System
- Systemic Treatments for Unresectable Pleural Mesothelioma: A Review of the Literature
- Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
- Tumor Treating Fields (TTFields) for Pleural Mesothelioma